344 related articles for article (PubMed ID: 27900865)
1. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
Murín J; Pernický M; Kiňová S
Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
3. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
4. Future of cholesteryl ester transfer protein inhibitors.
Rader DJ; deGoma EM
Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
[TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Filippatos TD; Klouras E; Barkas F; Elisaf M
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
[TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C
PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732
[TBL] [Abstract][Full Text] [Related]
7. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Goldberg AS; Hegele RA
Drug Des Devel Ther; 2012; 6():251-9. PubMed ID: 23055695
[TBL] [Abstract][Full Text] [Related]
9. [HDL and CETP in atherogenesis].
Pöss J; Böhm M; Laufs U
Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
[TBL] [Abstract][Full Text] [Related]
10. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
11. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Schaefer EJ
Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
[TBL] [Abstract][Full Text] [Related]
12. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
13. CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.
Tardif JC; Rhainds D; Rhéaume E; Dubé MP
Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):396-400. PubMed ID: 28126828
[TBL] [Abstract][Full Text] [Related]
14. Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
Eyvazian VA; Frishman WH
Cardiol Rev; 2017; 25(2):43-52. PubMed ID: 28099220
[TBL] [Abstract][Full Text] [Related]
15. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
16. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Doggrell SA
Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
[TBL] [Abstract][Full Text] [Related]
17. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
18. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
[TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
20. The end of the road for CETP inhibitors after torcetrapib?
Joy T; Hegele RA
Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
